MoonLake Immunotherapeutics
NASDAQ:MLTX
50.67 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Assets: | ||||
| Current Assets: | ||||
| Cash & Cash Equivalents
| 451.169 | 39.506 | 8.039 | 1.336 |
| Short Term Investments
| 59.839 | 32.609 | 0 | 0 |
| Cash and Short Term Investments
| 511.008 | 72.115 | 8.039 | 1.336 |
| Net Receivables
| 1.057 | 0.217 | 0.149 | 0 |
| Inventory
| 0 | 0 | 1.322 | 0 |
| Other Current Assets
| 2.102 | 4.179 | 0.127 | 0.283 |
| Total Current Assets
| 514.167 | 76.511 | 9.637 | 1.619 |
| Non-Current Assets: | ||||
| Property, Plant & Equipment, Net
| 3.949 | 0.332 | 0.046 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 115.043 | 115.015 |
| Tax Assets
| 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 8.423 | -0 | -115.043 | 0 |
| Total Non-Current Assets
| 12.373 | 0.332 | 0.046 | 115.015 |
| Total Assets
| 526.54 | 76.843 | 9.682 | 116.634 |
| Liabilities & Equity: | ||||
| Current Liabilities: | ||||
| Account Payables
| 0.553 | 0.255 | 1.428 | 0 |
| Short Term Debt
| 1.198 | 0.154 | 15 | 0.058 |
| Tax Payables
| 0.368 | 0.11 | 0.064 | 0 |
| Deferred Revenue
| -0.185 | 0 | 0 | 0 |
| Other Current Liabilities
| 8.4 | 7.257 | 4.659 | 0.067 |
| Total Current Liabilities
| 9.966 | 7.665 | 21.088 | 0.125 |
| Non-Current Liabilities: | ||||
| Long Term Debt
| 2.5 | 0.129 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0.583 | 0.282 | 0.24 | 4.025 |
| Total Non-Current Liabilities
| 3.083 | 0.411 | 0.24 | 4.025 |
| Total Liabilities
| 13.049 | 8.077 | 21.327 | 4.15 |
| Equity: | ||||
| Preferred Stock
| 0 | 0 | 0.072 | 0 |
| Common Stock
| 0.006 | 0.005 | 0.039 | 115 |
| Retained Earnings
| -116.657 | -80.65 | -53.644 | -2.517 |
| Accumulated Other Comprehensive Income/Loss
| 2.358 | 0.351 | -0.168 | 0 |
| Other Total Stockholders Equity
| 609.969 | 129.192 | 42.056 | 0 |
| Total Shareholders Equity
| 495.676 | 48.898 | -11.645 | 112.484 |
| Total Equity
| 513.491 | 68.767 | -11.645 | 112.484 |
| Total Liabilities & Shareholders Equity
| 526.54 | 76.843 | 9.682 | 116.634 |